Request Sample Inquiry
Diabetic Macular Edema Market

Diabetic Macular Edema Market

Diabetic Macular Edema Market Global Industry Assessment & Forecast

# Pages:


Base Year:


Nov - 2021


Report Code:


Segments Covered
  • By Indication Type, diffuse diabetic macular edema, focal diabetic macular edema
  • By Treatment Type anti-VEGF, corticosteroids, laser photocoagulation therapy, other off-label drugs
  • By End User hospitals, clinics, home care
Forecast YearsForecast Years: 2021 - 2028
Historical YearsHistorical Years: 2016 - 2020
Revenue 2021Revenue 2021: 3.7 Billion
Revenue 2028Revenue 2028: 4.74 Billion
Revenue CAGRRevenue CAGR (2021 - 2028): 3.15
Fastest Growing Region Fastest Growing Region (2022 - 2028) North America
Customization Offered
  • Cross-segment Market Size and Analysis for Mentioned Segments
  • Additional Company Profiles (Upto 5 With No Cost)
  • Additional Countries (Apart From Mentioned Countries)
  • Country/Region-specific Report
  • Go To Market Strategy
  • Region Specific Market Dynamics
  • Region Level Market Share
  • Import Export Analysis
  • Production Analysis
  • Others Request Customization Speak To Analyst
Frequently Asked Question
  • The global Diabetic Macular Edema valued at 3.7 Billion in 2020 and is expected to reach 4.74 Billion in 2028 growing at a CAGR of 3.15%.

  • The prominent players in the market are Pfizer Inc., Bayer AG, Bausch & Lomb Incorporated, Allergan Inc., F. Hoffmann-La Roche Ltd., Regeneron Pharmaceuticals Inc., ShahidBeheshti University of Medical Sciences., Johns Hopkins University, Novartis AG, The National Eye Institute..

  • The market is project to grow at a CAGR of 3.15% between 2021 and 2028.

  • The driving factors of the Diabetic Macular Edema include

    • The increasing research & development activities for the treatment of diabetic macular edema is likely to accelerate the growth of the diabetic macular edema treatment market during the forecast period.
    • Additionally, advancements in ophthalmic surgery techniques and R&D investment by pharmaceutical companies is further expected to boost the growth of the market in the years to come.

  • North America was the leading regional segment of the Diabetic Macular Edema in 2020.